Association of Anti–Factor Xa–Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Surgery"
DOI: 10.1001/jamasurg.2017.3787
Abstract: Importance The efficacy of anti–factor Xa (anti-Xa)–guided dosing of thromboprophylaxis after trauma remains controversial. Objective To assess whether dosing of enoxaparin sodium based on peak anti-Xa levels is associated with the venous thromboembolism (VTE) rate… read more here.
Keywords: vte; group; trauma; guided dosing ... See more keywords
Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.01.018
Abstract: OBJECTIVES Pemetrexed is indicated for non-small cell lung cancer and mesothelioma. Dosing is based on body surface are (BSA), while renal function is the only determinant for exposure and thus toxicity. BSA-based dosing introduces large… read more here.
Keywords: dosing pemetrexed; guided dosing; impairment; pharmacokinetically guided ... See more keywords
Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and translational science"
DOI: 10.1111/cts.13069
Abstract: Sorafenib improves outcomes in adult hepatocellular carcinoma; however, hand foot skin reaction (HFSR) is a dose limiting toxicity of sorafenib that limits its use. HFSR has been associated with sorafenib systemic exposure. The objective of… read more here.
Keywords: hepatocellular carcinoma; using pharmacokinetically; study; sorafenib ... See more keywords
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia
Sign Up to like & getrecommendations! Published in 2020 at "Trials"
DOI: 10.1186/s13063-020-04912-z
Abstract: Background Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide. Hydroxyurea is the primary disease-modifying therapy for the SCD, with proven benefits… read more here.
Keywords: trial; hydroxyurea optimization; study; guided dosing ... See more keywords
Safety and tolerability of 5-FU, irinotecan (IRI), and nab-paclitaxel (FOLFIRABRAX) with genotype-guided dosing of IRI in previously untreated patients with advanced gastrointestinal (GI) malignancies.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.423
Abstract: 423Background: 5-FU, IRI, and nab-paclitaxel (NP) are active in advanced GI cancers; the combination (FOLFIRABRAX) has not been evaluated. UGT1A1 clears SN-38, the active metabolite of IRI. UGT1A1*28 polymorphism reduces enzymatic activity and predisposes to… read more here.
Keywords: nab paclitaxel; iri nab; folfirabrax genotype; guided dosing ... See more keywords
Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3574
Abstract: 3574Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA repeats) and UGT1A1*93 (SNP -3156G > A) are significantl... read more here.
Keywords: pharmacokinetic analysis; genotype guided; ugt1a1 genotype; safety pharmacokinetic ... See more keywords
Corrigendum: Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2019.00251
Abstract: [This corrects the article DOI: 10.3389/fphar.2018.01316.]. read more here.
Keywords: pharmacodynamic model; corrigendum population; population pharmacokinetic; guided dosing ... See more keywords
Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1184523
Abstract: Fluoropyrimidines are chemotherapeutic agents widely used for the treatment of various solid tumors. Commonly prescribed FPs include 5-fluorouracil (5-FU) and its oral prodrugs capecitabine (CAP) and tegafur. Bioconversion of 5-FU prodrugs to 5-FU and subsequent… read more here.
Keywords: guided dosing; toxicity; beyond dpyd; dosing guidelines ... See more keywords